These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 33950515)

  • 1. The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patients.
    Shah R; Chan KKW
    Int J Cancer; 2021 Sep; 149(5):1031-1043. PubMed ID: 33950515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016.
    Shah M; Parmar A; Chan KKW
    Cancer Med; 2020 May; 9(10):3407-3416. PubMed ID: 32196964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience.
    Kumachev A; Trudeau ME; Chan KK
    Cancer; 2016 Mar; 122(6):893-8. PubMed ID: 26696022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
    Shida D; Yoshida T; Tanabe T; Tsukamoto S; Ochiai H; Kanemitsu Y
    Ann Surg Oncol; 2018 Jun; 25(6):1646-1653. PubMed ID: 29572704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada.
    Booth CM; Li G; Zhang-Salomons J; Mackillop WJ
    Cancer; 2010 Sep; 116(17):4160-7. PubMed ID: 20681012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study.
    Thein HH; Anyiwe K; Jembere N; Yu B; De P; Earle CC
    PLoS One; 2017; 12(10):e0186350. PubMed ID: 29020052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Yamaguchi T; Iwasa S; Nagashima K; Ikezawa N; Hamaguchi T; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Yamada Y; Shimada Y
    Anticancer Res; 2016 Jul; 36(7):3531-6. PubMed ID: 27354619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
    Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
    Hayashi K; Mitani S; Taniguchi H; Yasui H; Muro K; Mori K; Gotoda T; Yamazaki K
    Oncology; 2019; 96(3):132-139. PubMed ID: 30359979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
    Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of socioeconomic status on survival in stage III colon cancer patients: A retrospective cohort study using the SEER census-tract dataset.
    Dhahri A; Kaplan J; Naqvi SMH; Brownstein NC; Ntiri SO; Imanirad I; Felder SI; Dineen SP; Sanchez J; Dessureault S; Carballido E; Powers BD
    Cancer Med; 2021 Aug; 10(16):5643-5652. PubMed ID: 34197047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Popov I; Milicević M; Radosević-Jelić Lj
    Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis.
    Oake JD; Harasemiw O; Tangri N; Ferguson TW; Saranchuk JW; Bansal RK; Drachenberg DE; Nayak JG
    J Urol; 2021 Nov; 206(5):1204-1211. PubMed ID: 34181467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
    Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
    Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
    Payette E; Sarker S; Chalchal H
    Can J Rural Med; 2017; 22(4):148-152. PubMed ID: 28925914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
    Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
    Tai CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Chao Y; Teng HW
    Am J Clin Oncol; 2020 Jan; 43(1):28-34. PubMed ID: 31693507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.